Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27557913 | 0.88 | SMN1; SMN2 (0.44) | SMN1; SMN2USP2L3MBTL1ADORA1HPGD | |
| SCHEMBL21749177 | 0.85 | HPGD (0.40) | SMN1; SMN2USP2L3MBTL1ADORA1HPGD | |
| SCHEMBL2206945 | 0.85 | SMN1; SMN2 (0.46) | SMN1; SMN2USP2L3MBTL1ADORA1HPGD | |
| SCHEMBL31566504 | 0.85 | USP2 (0.41) | SMN1; SMN2USP2L3MBTL1ADORA1HPGD | |
| SCHEMBL5896147 | 0.84 | USP2 (0.49) | SMN1; SMN2USP2HPGDTSHREPHX2 | |
| SCHEMBL1147479 | 0.84 | SMN1; SMN2 (0.45) | SMN1; SMN2USP2L3MBTL1ADORA1HPGD | |
| SCHEMBL442966 | 0.84 | SMN1; SMN2 (0.45) | SMN1; SMN2USP2L3MBTL1ADORA1HPGD | |
| SCHEMBL19216685 | 0.83 | USP2 (0.40) | SMN1; SMN2USP2L3MBTL1ADORA1HPGD | |
| SCHEMBL25737087 | 0.83 | USP2 (0.42) | SMN1; SMN2USP2L3MBTL1ADORA1HPGD | |
| SCHEMBL606159 | 0.83 | USP2 (0.42) | SMN1; SMN2USP2L3MBTL1ADORA1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106795146-B | Isoxazole derivatives as inhibitors of mutant isocitrate dehydrogenase 1 | 第一三共株式会社 | 2020-06-26 | — | — | CN | disclosed |
| EP-3202766-B1 | ISOXAZOLE DERIVATIVE AS MUTATED ISOCITRATE DEHYDROGENASE 1 INHIBITOR | DAIICHI SANKYO CO LTD (JP) | 2019-12-25 | — | — | EP | disclosed |
| US-10040791-B2 | Isoxazole derivative as mutant isocitrate dehydrogenase 1 inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-08-07 | — | — | US | disclosed |
| US-10040791-B2 | Isoxazole derivative as mutant isocitrate dehydrogenase 1 inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2018-08-07 | — | — | US | disclosed |
| US-20170313696-A1 | ISOXAZOLE DERIVATIVE AS MUTANT ISOCITRATE DEHYDROGENASE 1 INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-11-02 | — | — | US | disclosed |
| US-20170313696-A1 | ISOXAZOLE DERIVATIVE AS MUTANT ISOCITRATE DEHYDROGENASE 1 INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-11-02 | — | — | US | disclosed |
| EP-3202766-A1 | ISOXAZOLE DERIVATIVE AS MUTATED ISOCITRATE DEHYDROGENASE 1 INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2017-08-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313696-A1 | ISOXAZOLE DERIVATIVE AS MUTANT ISOCITRATE DEHYDROGENASE 1 INHIBITOR | IDH1, IDH3A, IDH3B | SMN1; SMN2 2777/4885USP2 2181/4885L3MBTL1 1403/4885 |
| US-10040791-B2 | Isoxazole derivative as mutant isocitrate dehydrogenase 1 inhibitor | IDH1, IDH3A, IDH3B | SMN1; SMN2 2777/4885USP2 2181/4885L3MBTL1 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.